63bab58e-1dfd-43df-8188-4b8d766913f3
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 37
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.470
- DNA_REPAIR+0.350
- MYC_TARGETS_V1+0.330
- E2F_TARGETS+0.300
- OXIDATIVE_PHOSPHORYLATION+0.280
- PEROXISOME+0.250
- FATTY_ACID_METABOLISM+0.180
- CHOLESTEROL_HOMEOSTASIS+0.130
- G2M_CHECKPOINT+0.090
- WNT_BETA_CATENIN_SIGNALING+0.070
Top 10 suppressed
- INFLAMMATORY_RESPONSE-0.540
- INTERFERON_GAMMA_RESPONSE-0.540
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.510
- INTERFERON_ALPHA_RESPONSE-0.490
- IL6_JAK_STAT3_SIGNALING-0.480
- ALLOGRAFT_REJECTION-0.470
- TNFA_SIGNALING_VIA_NFKB-0.460
- UV_RESPONSE_DN-0.460
- COMPLEMENT-0.380
- KRAS_SIGNALING_UP-0.380
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-CQ-6225-01A-11R-1915-07 | — | — | 0.925 |
| 2 | 513fb61a-1339-45d2-8963-6337e3aff5df | — | — | 0.905 |
| 3 | f8d9864e-e148-4e60-9d9d-3df2897050cd | — | — | 0.905 |
| 4 | SRR12475110 | — | — | 0.901 |
| 5 | MDT-AP-0421 | Med | Medulloblastoma | 0.898 |
| 6 | TCGA-MZ-A6I9-01A-11R-A31N-07 | — | — | 0.896 |
| 7 | SRR8518240 | — | E | 0.896 |
| 8 | TCGA-P3-A6T6-01A-11R-A34R-07 | — | — | 0.894 |
| 9 | ERR2208933 | — | — | 0.893 |
| 10 | R207 | — | — | 0.888 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.470 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.350 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.330 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.300 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.280 | Remibrutinib | — uncovered |
| PEROXISOME | 0.250 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.130 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.090 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.040 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.030 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.010 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.010 | Inavolisib | — uncovered |